156 related articles for article (PubMed ID: 21591514)
1. Clinical application of tumour markers: a review.
Amayo AA; Kuria JG
East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
5. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
[TBL] [Abstract][Full Text] [Related]
6. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract][Full Text] [Related]
7. RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS.
Plavetić ND; Gnjidić M; Kulić A; Ivić M; Kukec I; Vidović M
Lijec Vjesn; 2016; 138(3-4):85-92. PubMed ID: 30146854
[TBL] [Abstract][Full Text] [Related]
8. [Standards, options and recommendations for tumor markers in colorectal cancer].
Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
[TBL] [Abstract][Full Text] [Related]
9. [Clinical relevance of tumor markers].
Lamerz R
Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
[TBL] [Abstract][Full Text] [Related]
10. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the clinical use of tumour markers.
Duffy MJ
Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M
Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463
[TBL] [Abstract][Full Text] [Related]
13. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of abnormal levels of serum tumour markers in elderly people.
Lopez LA; Del Villar V; Ulla M; Fernandez F; Fernandez LA; Santos I; Rabadan L; Gutierrez M
Age Ageing; 1996 Jan; 25(1):45-50. PubMed ID: 8670528
[TBL] [Abstract][Full Text] [Related]
15. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
16. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness.
Arioli D; Pipino M; Boldrini E; Amateis E; Cristani A; Ventura P; Romagnoli E; De Santis MC; Zeneroli ML
Intern Emerg Med; 2007 Jun; 2(2):88-94. PubMed ID: 17622496
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of tumour markers.
Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
[TBL] [Abstract][Full Text] [Related]
20. Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: Results from a 12-year experience.
Wen YH; Chang PY; Hsu CM; Wang HY; Chiu CT; Lu JJ
Clin Chim Acta; 2015 Oct; 450():273-6. PubMed ID: 26344337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
